Interestingly, MGMT was found hypermethylated in all long-term survivors (LTS) GBM patients, defined as those patients with a median survival time of more than 3 years [51], proving the study of this gene as a clinically relevant predictor of response to treatment in glioma patients [52]. This evidence concerns the gene MGMT and central nervous system cancer.